The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy

Launched by WRIGHT STATE UNIVERSITY · Jan 9, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a cream called imipramine used together with a treatment called photodynamic therapy (PDT) for patients with actinic keratosis, which are pre-cancerous spots on the skin. The researchers want to see if using imipramine before PDT can reduce pain during the procedure and improve its effectiveness. While both treatments are approved for use, this study is exploring a new way to combine them.

To participate in the trial, you need to be at least 18 years old and have been advised by your doctor to receive PDT for your skin condition. You should have fair skin, as this study focuses on individuals with certain skin types that have actinic damage. Participants will need to agree to avoid excessive sun exposure and certain medications during the study. If you join, you can expect to receive both treatments as part of your care, and the researchers will monitor how well you do with this new approach.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female ages 18 and older
• • Skin type must be "Fair", Fitzpatrick type I to III, due to the presence of actinic damage in this population.
• • Subjects need to have a physician's order to receive PDT treatment on their face, scalp or forearms.
• • Willing to participate and understand the informed consent document.
• • Willing to avoid excess sun exposure/tanning beds to the area to be treated with PDT.
• Exclusion Criteria:
• • Those currently taking any tricyclic antidepressants (TCAs)
• • Those currently taking any selective serotonin reuptake inhibitor (SSRI)
• • Those with porphyria
• • Large tattoos in the treated areas
• • Pregnancy or nursing
• • Taking any oral or topical medications that could interfere with the PDT (Appendix A)
• • Active rashes in the area